Expression of cardiotrophin-1 and effects of irbesartan in adriamycin induced cardiomyopathy in rats.
- Author:
Han-Ping ZHUANG
1
;
Jia-Mei YAO
;
Ying CHEN
;
Chuan-Chang LI
Author Information
1. Department of Gerontology, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Angiotensin II Type 1 Receptor Blockers;
pharmacology;
Animals;
Biphenyl Compounds;
pharmacology;
Cardiomyopathies;
chemically induced;
metabolism;
Cytokines;
metabolism;
Doxorubicin;
adverse effects;
Irbesartan;
Male;
Myocytes, Cardiac;
metabolism;
Rats;
Rats, Sprague-Dawley;
Tetrazoles;
pharmacology;
Ventricular Remodeling;
drug effects
- From:
Journal of Central South University(Medical Sciences)
2007;32(4):574-578
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate cardiotrophin-1(CT-1) expression in the ventricle and the effects of angiotensin II type I receptor antagonist (AT(1)RA) irbesartan on the ventricular remodeling in adriamycin myocardiopathy.
METHODS:Thirty male SD rats were randomized into 2 groups: a control group (n=10) and a model group (n=20). The model group was administered adriamycin and 18 rats survived. And theses rats were randomized again into 2 groups. One was treated with irbesartan [50 mg/(kg x d), with stomach-tube], and the other received equal saline, so did the control group. After 12 weeks, the protein level of CT-1 was detected by immunohistochemistry.
RESULTS:Ventricular CT-1 in the model control group and the treatment group was higher than that in the control group and the correlation analysis showed that ventricular CT-1 of the model control group was positively correlated with the left ventricular weight index, and CT-1 of the treatment group was lower than that of the model control group.
CONCLUSION:CT-1 was assumed to take part in the ventricular remodeling. The mechanism of irbesartan on the ventricular remodeling may be related to the downregulation of CT-1 expression.
